Ipsen Pharma issued a corrective statement to amend its previously published monthly disclosure of the total number of shares and voting rights as of June 30, 2026. The correction addresses a material error in the reported gross and net voting rights figures. The updated totals are 83,814,526 shares, with 132,090,665 gross voting rights and 130,884,189 net voting rights. This correction ensures accurate shareholder information in compliance with French financial regulations.
Ipsen Pharma issued a correction to its monthly report on the total number of shares and voting rights as of June 30, 2026. The correction addresses a material error in the previously published figures for both gross and net voting rights. The update...
Alstom announced a 4.9% increase in revenue to €4.734 billion for Q1 of fiscal year 2026/27, driven by strong performance in rolling stock, services, and signaling. Despite a 37% drop in new orders to €2.56 billion, the company achieved major operati...
Alstom posted a 4.9% increase in sales to €4.73 billion for Q1 FY 2026/27, driven by progress in rolling stock, services, and signalling. Despite a 37% drop in orders to €2.56 billion, the company achieved major milestones including TGV-M homologatio...
Teledyne Technologies reported strong Q2 2026 results, with earnings per share of $6.28 beating estimates by 8.65% and revenue of $1.66 billion surpassing expectations. The company saw a 20.8% increase in EPS and a 9.8% rise in revenue year-over-year...
QuantumScape, a solid-state battery developer for electric vehicles, is expected to report a Q2 2026 loss of $0.18 per share and $1 million in revenue, reflecting ongoing investment in its pilot production. Despite being unprofitable with a negative ...
